Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Study
  • Published:

Disseminated coccidioidomycosis in a patient managed with adalimumab for Crohn's disease

Nature Reviews Gastroenterology & Hepatology volume 7, pages 231–235 (2010)Cite this article

Subjects

Abstract

Background. A 50-year-old man presented with a 2–3 month history of left lower quadrant abdominal pain, right periorbital headache, blurry vision, tinnitus, polydipsia, right elbow pain, and a 32 kg weight loss over the past year. He had a 34-year history of complicated Crohn's disease that was notable for surgical stricture repair and partial colectomy for bowel perforation. The patient was receiving mesalazine and 6-mercaptopurine and, 2 months before admission, had stopped a 4-month therapy course with the biologic agent adalimumab for treatment of Crohn's disease.

Investigations. Physical examination, brain and elbow MRI scans, chest CT scan, routine blood analyses, assessment of coccidioidomycosis antibody levels, immunodiffusion and complement fixation studies in serum and cerebrospinal fluid, full-body technetium-99m nuclear bone scan, hematoxylin and eosin staining of resected tissue specimens.

Diagnosis. Disseminated coccidioidomycosis with meningeal, bone, soft tissue and pulmonary involvement.

Management. The patient underwent treatment with amphotericin B liposomal complex and oral fluconazole and right elbow surgical debridement and irrigation. All immunosuppressive therapy was stopped.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

References

  1. Galgiani, J. N. et al. Coccidioidomycosis. Clin. Infect. Dis. 41, 1217–1223 (2005).

    Article  PubMed  Google Scholar 

  2. Bergstrom, L. et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum. 50, 1959–1966 (2004).

    Article  CAS  PubMed  Google Scholar 

  3. Saubolle, M. A., McKellar, P. P. & Sussland, D. Epidemiological, clinical, and diagnostic aspects of coccidioidomycosis. J. Clin. Microbiol. 45, 26–30 (2007).

    Article  CAS  PubMed  Google Scholar 

  4. Hector, R. F. & Laniado-Laborin, R. Coccidioidomycosis—a fungal disease of the Americas. PLoS Med. 2, e2 (2005).

    Article  PubMed Central  PubMed  Google Scholar 

  5. Crum, N. F., Lederman, E. R., Stafford, C. M., Parrish, J. S. & Wallace, M. R. Coccidioidomycosis: a descriptive survey of reemerging disease. Clinical characteristics and current controversies. Medicine (Baltimore) 83, 149–175 (2004).

    Article  Google Scholar 

  6. Ampel, N. M., Ryan, K. J., Carry, P. J., Wieden, M. A. & Schifman, R. B. Fungemia due to Coccidioides immitis. An analysis of 16 episodes in 15 patients and a review of the literature. Medicine (Baltimore) 65, 312–321 (1986).

    Article  CAS  Google Scholar 

  7. Jones, J. L. et al. Coccidioidomycosis among persons with AIDS in the United States. J. Infect. Dis. 171, 961–966 (1995).

    Article  CAS  PubMed  Google Scholar 

  8. Hernández, J. L., Echevarría, S., García-Valtuille, A., Mazorra, F. & Salesa, R. Atypical coccidioidomycosis in an AIDS patient successfully treated with fluconazole. Eur. J. Clin. Microbiol. Infect. Dis. 16, 592–594 (1997).

    Article  PubMed  Google Scholar 

  9. Slagle, D. C., Cox, R. A. & Kuruganti, U. Induction of tumor necrosis factor alpha by spherules of Coccidioides immitis. Infect. Immun. 57, 1916–1921 (1989).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Cox, R. A. & Magee, D. M. Production of tumor necrosis factor alpha, interleukin-1 alpha, and interleukin-6 during murine coccidioidomycosis. Infect. Immun. 63, 4178–4180 (1995).

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Olsen, N. J. & Stein, C. M. New drugs for rheumatoid arthritis. N. Engl. J. Med. 350, 2167–2179 (2004).

    Article  CAS  PubMed  Google Scholar 

  12. Papchristou, G. I. & Plevy, S. Novel biologics in inflammatory bowel disease. Gastroenterol. Clin. North Am. 33, 251–269 (2004).

    Article  Google Scholar 

  13. Feagan, B. G. et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results of the CHARM study. Gastroenterology 135, 1493–1499 (2008).

    Article  CAS  PubMed  Google Scholar 

  14. Loftus, E. V. et al. Effects of adalimumab maintenance therapy on health-related quality of life in patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am. J. Gastroenterol. 103, 3132–3141 (2008).

    Article  PubMed  Google Scholar 

  15. Tsiodras, S., Samonis, G., Boumpas, D. T. & Kontoyiannis, D. P. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin. Proc. 83, 181–194 (2008).

    Article  CAS  PubMed  Google Scholar 

  16. Colombel, J. F. et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132, 52–65 (2007).

    Article  CAS  PubMed  Google Scholar 

  17. Bongartz, T. et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275–2285 (2006).

    Article  CAS  PubMed  Google Scholar 

  18. Mitoma, H. et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept and adalimumab. Arthritis Rheum. 58, 1248–1257 (2008).

    Article  CAS  PubMed  Google Scholar 

  19. Listing, J. et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 52, 3403–3412 (2005).

    Article  CAS  PubMed  Google Scholar 

  20. Toruner, M. et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134, 929–936 (2008).

    Article  PubMed  Google Scholar 

  21. Abbott Laboratories. Humira®. RxAbbott [online], (2010).

  22. FDA. Information for healthcare professionals: Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab). FDA [online], (2010).

  23. Winthrop, K. L. & Chiller, T. Preventing and treating biologic-associated opportunistic infections. Nat. Rev. Rheumatol. 5, 405–410 (2009).

    Article  CAS  PubMed  Google Scholar 

  24. Blair, J. E. & Logan, J. L. Coccidioidomycosis in solid organ transplantation. Clin. Infect. Dis. 33, 1536–1544 (2001).

    Article  CAS  PubMed  Google Scholar 

  25. Galgiani, J. N. et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann. Intern. Med. 133, 676–686 (2000).

    Article  CAS  PubMed  Google Scholar 

  26. Johnson, R. H. & Einstein, H. E. Coccidioidal meningitis. Clin. Infect. Dis. 42, 103–107 (2006).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. David Geffen School of Medicine, UCLA, 10833 LeConte Avenue, 37-121 CHS, Los Angeles, 90095, CA, USA

    Sumeet S. Mitter

  2. Division of Pulmonary and Critical Care, UCLA, 10833 LeConte Avenue, 37-121 CHS, Los Angeles, 90095, CA, USA

    Ariss DerHovanessian

  3. Department of Pathology and Laboratory Medicine, UCLA, 10833 LeConte Avenue, 37-121 CHS, Los Angeles, 90095, CA, USA

    Joseph D. Hillman

  4. Division of Infectious Diseases, UCLA, 10833 LeConte Avenue, 37-121 CHS, Los Angeles, 90095, CA, USA

    Daniel Z. Uslan

Authors
  1. Sumeet S. Mitter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ariss DerHovanessian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph D. Hillman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniel Z. Uslan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Z. Uslan.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mitter, S., DerHovanessian, A., Hillman, J. et al. Disseminated coccidioidomycosis in a patient managed with adalimumab for Crohn's disease. Nat Rev Gastroenterol Hepatol 7, 231–235 (2010). https://doi.org/10.1038/nrgastro.2010.20

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2010.20

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing